Gilead Sciences has inked a joint procurement agreement (JPA) with the European Commission (EC) for the supply of up to 500,000 treatment courses …
The focus and resources of several biotech and pharma companies have shifted toward developing a vaccine or treatment for COVID-19. However, there are …
Gilead Sciences (GILD) is nearing a deal to buy biotech Immunomedics Inc for more than $20 billion, says the Wall Street Journal, which …
Dr. Reddy’s Laboratories along with its subsidiaries announced the launch of Gilead Sciences coronavirus drug candidate remdesivir under the brand name Redyx in …
Gilead’s (GILD) Kite has announced that it has submitted a supplemental Biologics License Application (sBLA) to the U.S.
Gilead Science’s (GILD) investigational antiviral Veklury (remdesivir) has now received expanded Emergency Use Authorization (EUA) from the FDA to treat all hospitalized patients …
Gilead Sciences Inc. could be granted additional emergency use authorization by US regulators for its drug remdesivir to include patients hospitalized with moderate …
Gilead Sciences (GILD) has received a complete response letter (CRL) from the U.S.
Gilead Sciences (GILD) and Tango Therapeutics have announced an expanded collaboration focusing on targeted immune evasion therapies for cancer patients. Under the deal, …
Gilead Sciences Inc. announced on Monday that it has filed a New Drug Application (NDA) with the US Food and Drug Administration (FDA) …
